Ian W. McLeod serves as Senior Vice President, Chief Accounting Officer, and Treasurer at Anika Therapeutics, Inc., a global medical technology company focused on innovative therapies for osteoarthritis and regenerative medicine. In this pivotal role, he oversees all aspects of the company's accounting operations, financial reporting, SEC compliance, internal controls, and treasury functions. Since joining Anika in 2021 as Vice President and Controller, McLeod has been instrumental in strengthening the financial infrastructure to support the company's growth, including its expansion into new markets and product launches such as the HYVIZ™ hyaluronic acid viscosupplement. Prior to Anika, McLeod held progressive leadership positions in finance and accounting at several prominent biotech and pharmaceutical firms. He served as Senior Director of Technical Accounting and Reporting at PTC Therapeutics, where he managed complex revenue recognition, lease accounting, and global financial consolidations during a period of rapid clinical and commercial expansion. Earlier, as Director of Accounting at Ironwood Pharmaceuticals, he led technical accounting initiatives and supported the company's initial public offering and subsequent equity financings. McLeod began his career at Deloitte & Touche, gaining foundational expertise in audit and advisory services for life sciences clients. A Certified Public Accountant, he holds a Bachelor of Science in Accounting from the University of Massachusetts Amherst. Under McLeod's stewardship, Anika has achieved enhanced financial transparency and operational efficiency, contributing to key milestones such as improved EBITDA margins and successful debt refinancing. His strategic foresight has been critical in navigating regulatory challenges and positioning the company for sustainable profitability amid evolving industry dynamics. McLeod's deep expertise in GAAP, SOX compliance, and biotech financial modeling continues to drive Anika's fiscal excellence.